May 29, 2020 / 10:12 AM / a month ago

BRIEF-Roche Says CHMP Recommends EU Approval Of Rozlytrek For Advanced Cell Lung Cancer

May 29 (Reuters) - Roche Holding AG:

* CHMP RECOMMENDS EU APPROVAL OF ROCHE’S ROZLYTREK FOR PEOPLE WITH NTRK FUSION-POSITIVE SOLID TUMOURS AND FOR PEOPLE WITH ROS1-POSITIVE, ADVANCED NON-SMALL CELL LUNG CANCER Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below